Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this observational study enrolled 1,336 participants who were already receiving chemotherapy as part of their usual care. The study was not testing a new treatment — instead, it was tracking and measuring a common side effect of chemotherapy called peripheral neuropathy (nerve damage that can cause tingling, numbness, or pain, usually in the hands and feet). Participants completed questionnaires and assessments, and 1,114 people completed the study, while 222 did not. The reported data shows that the main thing being measured was how many participants developed peripheral neuropathy during the study, defined as a meaningful increase in nerve-related symptoms on a standard questionnaire scale (called the CIPN-20) compared to their starting point, measured up to 24 weeks. According to the results reported on ClinicalTrials.gov, 792 out of the 1,336 participants who started the study showed this level of increase in peripheral neuropathy symptoms. The study also set out to measure several other things, including changes to treatment doses, quality of life, and patient-reported symptom burden — however, the results data for all of those secondary outcomes was not reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Ovarian Cancer Trial, Active, Not Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with stage I, II, or III lung cancer (non-small cell type), breast cancer, or ovarian cancer — stage IV does not qualify.
- You are planning to start chemotherapy using a taxane-based drug (such as docetaxel or paclitaxel) within 14 days of signing up for the trial, as part of one of the specific treatment plans approved for this study.
- You may also be taking part in another clinical trial at the same time, as long as your chemotherapy regimen is one of the ones approved for this study.
- You have never previously received certain types of chemotherapy, including taxanes (paclitaxel or docetaxel), platinum drugs (such as cisplatin or carboplatin), vinca alkaloids (such as vincristine), or bortezomib.
- You are able to fill out health questionnaires in English or Spanish, and are willing to complete them at all required appointments — including one before you join the trial.
- You already have nerve damage (neuropathy), including from conditions like diabetes, multiple sclerosis, or Parkinson's disease — this does not stop you from joining.
- You are willing to provide required biological samples (such as blood or tissue) for research purposes.
- You have been given the chance to provide additional optional samples for future research, and have given your answer (either yes or no).
- You have been told about the research nature of this study and have signed a consent form agreeing to take part.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have stage IV (advanced/spread) lung, breast, or ovarian cancer.
- You have previously received chemotherapy with taxanes, platinum drugs, vinca alkaloids, or bortezomib before joining the trial.
- You are not planning to use one of the specific chemotherapy regimens approved for this study.
- You are unable or unwilling to complete the required health questionnaires in English or Spanish.
- You are not willing to provide the required biological samples for research (confirm with trial site).
- Your treatment hospital does not have current approval from its ethics/review board to run this study (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Number of Participants With Development of Peripheral Neuropathy
Other options
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.